Related Experiment Video
Updated: May 21, 2026
07:22
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
1,5-Anhydroglucitol: From Short-Term Glycemic Monitoring to Risk Stratification of Diabetes Complications
Huijuan Xu1,2, Qiwei Tang1,2, Qiu Chen1
1Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, People's Republic of China.
Summary
1,5-anhydroglucitol (1,5-AG) effectively monitors short-term glycemic control and is linked to various diabetes complications. Salivary 1,5-AG offers a promising, non-invasive approach for patient monitoring and risk assessment.
Area of Science:
- Biochemistry and Endocrinology
- Diabetes Mellitus Research
- Clinical Diagnostics
Background:
- 1,5-anhydroglucitol (1,5-AG) reflects short-term glycemic fluctuations and postprandial hyperglycemia.
- Elevated 1,5-AG levels are associated with numerous diabetic complications, including nephropathy, retinopathy, and cardiovascular diseases.
Purpose of the Study:
- To review the clinical application value and research status of 1,5-AG in diabetes complications.
- To highlight the potential of salivary 1,5-AG as a non-invasive biomarker.
Main Methods:
- Systematic review of existing literature on 1,5-AG.
- Analysis of studies correlating 1,5-AG levels with diabetes complications.
- Evaluation of salivary 1,5-AG detection methods and clinical prospects.
Main Results:
- 1,5-AG is a sensitive indicator for glycemic variability and a predictor of diabetic complications.
- Salivary 1,5-AG demonstrates high patient compliance and clinical potential.
- Current detection methods for 1,5-AG require further optimization.
Conclusions:
- 1,5-AG is a valuable biomarker for diabetes complication risk stratification.
- Salivary 1,5-AG offers a promising non-invasive monitoring tool.
- Further research is needed to refine 1,5-AG detection and clinical application.
Related Concept Videos
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...